The U.S. Food and Drug Administration has approved a single shared Risk Evaluation and Mitigation Strategy (REMS) for transmucosal immediate-release fentanyl (TIRF) products. This new system will replace individual REMS and allow prescribers to enroll into just one system. Read more.
© 2020 HealthCom Media
All rights reserved. No part of this website or publication may be reproduced, stored, or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the copyright holder